Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - Time to Buy?

Key Points

• Assembly Biosciences’ trading volume surged 378% to approximately 885,000 shares, while the stock rose 0.3% to $25.52.
• Analyst sentiment is generally favorable, with a “Moderate Buy” consensus and an average price target of $45.60, although Weiss Ratings maintained a “sell” rating.
• The company exceeded quarterly expectations, reporting a loss of $0.20 per share versus the expected $0.72 loss and revenue of $13.37 million versus the $8.60 million consensus estimate.

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) shares saw an uptick in trading volume on Tuesday . Approximately 884,983 shares were traded during trading, an increase of 378% from the previous session's volume of 185,122 shares.The stock last traded at $25.5190 and had previously closed at $25.44.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Mizuho set a $53.00 target price on Assembly Biosciences in a report on Tuesday, September 1st. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Tuesday, August 18th. Guggenheim restated a "buy" rating and issued a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Finally, UBS Group started coverage on shares of Assembly Biosciences in a research note on Tuesday, September 1st. They set a "buy" rating and a $52.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $45.60.

Assembly Biosciences Stock Up 0.3%

The stock has a market capitalization of $519.57 million, a P/E ratio of 25.01 and a beta of 1.13. The business's 50 day simple moving average is $29.52 and its two-hundred day simple moving average is $28.23.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. Analysts predict that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current year.

Institutional Investors Weigh In On Assembly Biosciences

Institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in shares of Assembly Biosciences in the 4th quarter worth $147,000. Bank of America Corp DE lifted its position in shares of Assembly Biosciences by 113.3% during the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company's stock worth $303,000 after buying an additional 5,792 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Assembly Biosciences by 69.4% in the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company's stock worth $434,000 after buying an additional 6,411 shares during the last quarter. Engineers Gate Manager LP grew its holdings in shares of Assembly Biosciences by 88.5% in the second quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company's stock valued at $488,000 after acquiring an additional 8,343 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $660,000. Institutional investors own 19.92% of the company's stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a clinical-stage biotechnology company developing oral therapies for serious viral infections. Its research programs have focused primarily on chronic hepatitis B virus (HBV) infection and herpesvirus diseases, with the goal of addressing areas where existing treatments may not provide a functional cure or durable disease control.

The company's pipeline includes investigational HBV capsid assembly modulators, including ABI-4334, designed to interfere with key stages of the HBV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.